CNCR Performance — Range Cancer Therapeutics ETF
Data updated: 2025-04-28
CNCR returned −33.31% over one year to Feb 2025. Annualised returns are −14.88% over 3 years and −10.57% over 5 years. The fund trailed its Health Care Equity category average: $100 invested three years ago grew to $62, against $107 for the category, and to $67 over one year, against $99. Volatility over the past three years was 31.17% a year. In the 12 months to Feb 2025 the fund lost a net $4.3M, and assets reached $8.93M.
CNCR Growth of $100
What $100 invested in Range Cancer Therapeutics ETF grew to, compounded from monthly returns reported on SEC Form N-PORT, against the Health Care Equity category average over the same months.
| Period | CNCR | Category average |
|---|---|---|
| 1 year (Mar 2024 – Feb 2025) | $67 | $99 |
| 3 years (Mar 2022 – Feb 2025) | $62 | $107 |
| 5 years (Mar 2020 – Feb 2025) | $57 | $136 |
CNCR Trailing Returns
Total returns to Feb 2025, from SEC N-PORT.
| Period | Total return |
|---|---|
| 1 year | −33.31% |
| 3 years (annualised) | −14.88% |
| 5 years (annualised) | −10.57% |
CNCR Annual Returns
Calendar-year total returns of Range Cancer Therapeutics ETF, compounded from monthly SEC N-PORT returns. Partial years show the months covered.
| Year | Total return |
|---|---|
| 2025 (Jan–Feb) | −7.05% |
| 2024 | −9.00% |
| 2023 | −1.99% |
| 2022 | −41.81% |
| 2021 | −19.40% |
| 2020 (Mar–Dec) | +47.13% |
CNCR Monthly Returns
Monthly total returns as reported on SEC Form N-PORT.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | +0.5% | −7.5% | — | — | — | — | — | — | — | — | — | — |
| 2024 | +5.0% | +20.8% | −3.1% | −10.9% | −1.2% | −7.2% | +12.8% | −1.7% | −0.4% | −2.9% | −1.8% | −14.0% |
| 2023 | +7.8% | −9.7% | −10.5% | +5.4% | +5.2% | −3.3% | +0.4% | −7.0% | −9.2% | −10.9% | +12.7% | +23.0% |
| 2022 | −18.2% | −4.3% | −3.1% | −13.8% | −10.2% | +9.5% | +4.9% | −3.0% | −5.4% | +2.4% | −0.4% | −7.8% |
| 2021 | +3.2% | −3.5% | −5.4% | +2.9% | −0.3% | +4.0% | −8.9% | +5.6% | −0.8% | −5.2% | −7.2% | −4.5% |
| 2020 | — | — | −8.6% | +14.0% | +17.0% | +2.5% | −6.6% | +5.8% | +1.6% | −3.1% | +22.3% | −1.1% |
CNCR Risk
Risk measures from monthly returns over Mar 2022 – Feb 2025.
- 3-year volatility (annualised): 31.17%
- 3-year Sharpe ratio: -0.62 (vs 4.5% risk-free rate)
- Best month: +22.96% (Dec 2023)
- Worst month: −14.01% (Dec 2024)
CNCR Fund Flows
Monthly money in and out of Range Cancer Therapeutics ETF, from SEC Form N-PORT.
- 12-month net flow: −$4.3M
- 12-month gross sales (incl. reinvestments): $16.4M
- Sales ÷ redemptions: 0.79×
| Month | Sales | Redemptions | Net flow |
|---|---|---|---|
| Feb 2025 | $0 | $0 | $0 |
| Jan 2025 | $0 | $610K | −$610K |
| Dec 2024 | $0 | $0 | $0 |
| Nov 2024 | $0 | $0 | $0 |
| Oct 2024 | $0 | $2.2M | −$2.2M |
| Sep 2024 | $2.2M | $775K | $1.5M |
| Aug 2024 | $0 | $751K | −$751K |
| Jul 2024 | $0 | $1.4M | −$1.4M |
| Jun 2024 | $0 | $1.4M | −$1.4M |
| May 2024 | $0 | $755K | −$755K |
| Apr 2024 | $0 | $8.6M | −$8.6M |
| Mar 2024 | $14.1M | $4.1M | $10.0M |
CNCR Assets Under Management
Net assets of Range Cancer Therapeutics ETF by report date, from SEC N-PORT filings.
| Report date | Net assets |
|---|---|
| 2025-02-28 | $8.93M |
| 2024-11-30 | $11.89M |
| 2024-08-31 | $13.26M |
| 2024-05-31 | $16.53M |
| 2024-02-29 | $19.39M |
| 2023-11-30 | $11.33M |
| 2023-08-31 | $9.64M |
| 2023-05-31 | $13.33M |
| 2023-02-28 | $19.48M |
| 2022-11-30 | $22.43M |
| 2022-08-31 | $23.23M |
| 2022-05-31 | $20.16M |
For information only. Not investment advice: figures are as reported in SEC filings and may contain errors or be out of date. Past performance does not guarantee future results.